What is the recommended workup and treatment for a 64-year-old with intermittent claudication of the left calf that improves with rest and a normal lower extremity exam?

Workup and Management of Intermittent Claudication

This 64-year-old patient with classic intermittent claudication should undergo ankle-brachial index (ABI) testing to confirm peripheral artery disease, followed by initiation of supervised exercise therapy, cilostazol (if no heart failure), and antiplatelet therapy with aspirin or clopidogrel to reduce cardiovascular risk and improve walking distance. 1

Initial Diagnostic Workup

Obtain an ankle-brachial index (ABI) as the primary diagnostic test to confirm peripheral artery disease and establish disease severity. 1 The ABI is calculated by dividing the highest ankle systolic pressure by the highest brachial systolic pressure. An ABI ≤0.90 confirms PAD, while 0.91-0.99 is considered borderline abnormal. 1

Key Physical Examination Findings to Document:

• Pulse examination: Palpate and grade femoral, popliteal, dorsalis pedis, and posterior tibial pulses (0=absent, 1=diminished, 2=normal, 3=bounding). 1 Absence of posterior tibial pulse is more accurate for PAD diagnosis than absent dorsalis pedis pulse. 1
• Auscultation: Listen for femoral bruits. 1
• Skin inspection: Examine for hair loss, skin temperature, color changes, and any nonhealing wounds. 1

Important caveat: The absence of swelling, tenderness, redness, or warmth makes deep vein thrombosis unlikely but does not exclude PAD—these inflammatory signs are typically absent in chronic arterial insufficiency. 1

First-Line Treatment Strategy

1. Supervised Exercise Therapy (Class I Recommendation)

Enroll the patient in a supervised exercise program as the initial and most effective treatment for claudication. 1 This provides superior outcomes compared to unsupervised "go home and walk" advice. 1

Specific exercise prescription parameters: 1

• Duration: 30-45 minutes per session
• Frequency: Minimum 3 times per week
• Duration of program: Minimum 12 weeks
• Technique: Intermittent walking to moderate-to-maximum claudication pain, alternating with rest periods
• Expected benefit: >100% improvement in peak walking distance

Alternative if supervised program unavailable: Structured community- or home-based exercise programs are reasonable alternatives, though evidence for unsupervised programs is less robust. 1 These should include health coaching, activity monitors, and specific progression guidelines. 1

2. Pharmacological Therapy for Claudication Symptoms

Initiate cilostazol 100 mg orally twice daily as first-line pharmacotherapy to improve symptoms and walking distance. 1 This is the only FDA-approved medication for symptomatic treatment of claudication and improves maximal walking distance by 40-60% after 12-24 weeks. 1

Critical contraindication: Do not prescribe cilostazol if the patient has any history of heart failure, as it is a phosphodiesterase-3 inhibitor with potential adverse cardiac effects. 1

Second-line option: Pentoxifylline 400 mg three times daily may be considered if cilostazol is contraindicated or not tolerated, though its clinical effectiveness is marginal and not well established. 1

Avoid ineffective therapies: Do not prescribe chelation therapy (potentially harmful), vitamin E, L-arginine, propionyl-L-carnitine, or ginkgo biloba—these have no proven benefit or marginal/unestablished effectiveness. 1

3. Antiplatelet Therapy for Cardiovascular Risk Reduction

Prescribe either aspirin (75-325 mg daily) OR clopidogrel (75 mg daily) to reduce risk of myocardial infarction, stroke, and vascular death. 1 Both are Class I recommendations with equivalent efficacy for cardiovascular protection in symptomatic PAD. 1

Dual antiplatelet therapy consideration: The combination of aspirin plus clopidogrel may be considered only in high-risk patients without increased bleeding risk, though this is a Class IIb recommendation. 1

Recent evidence on rivaroxaban: Low-dose rivaroxaban (2.5 mg twice daily) plus aspirin further reduces cardiovascular events but increases bleeding risk—this should be reserved for carefully selected high-risk patients. 2, 3, 4

Do not add warfarin: Warfarin added to antiplatelet therapy provides no benefit and increases major bleeding risk. 1

4. Aggressive Risk Factor Modification

Cardiovascular risk reduction measures (all Class I): 1

• Smoking cessation: Counsel at every visit and offer pharmacotherapy (varenicline, bupropion, or nicotine replacement). 1
• Statin therapy: Prescribe high-intensity statins for lipid management and cardiovascular risk reduction. 2, 3
• Blood pressure control: Consider ACE inhibitors, particularly beneficial in patients with diabetes or hypertension. 2
• Diabetes management: Target hemoglobin A1C <7% to reduce microvascular complications. 1
• Foot care: Emphasize proper footwear, daily inspection, and prompt attention to any skin lesions. 1

When to Consider Revascularization

Reserve endovascular or surgical revascularization for patients with lifestyle-limiting or vocational disability who have failed conservative therapy (exercise and pharmacotherapy) or have very favorable risk-benefit anatomy (e.g., focal aortoiliac disease). 1

Imaging for revascularization planning: If symptoms persist despite 3-6 months of optimal medical therapy and exercise, obtain contrast-enhanced MRA or CTA to define anatomy and plan intervention. 1 MRA is particularly useful in patients with heavy calcification (diabetes, age >80). 1

Common Pitfalls to Avoid

• Do not skip the ABI: Clinical diagnosis alone is insufficient—objective testing is required. 1
• Do not prescribe cilostazol without screening for heart failure: This is an absolute contraindication. 1
• Do not rush to revascularization: Most patients improve significantly with exercise and medical therapy alone, and limb loss risk is only 1-3% over 5 years. 5
• Do not forget systemic atherosclerosis: PAD is a marker of systemic disease—these patients have significantly elevated cardiovascular mortality risk requiring aggressive risk factor modification. 2, 5, 3